Fumaric acid esters, their place in the treatment of psoriasis

British Journal of Dermatology

Volumn 150, Issue 4, 2004, Pages 630-632

  Ormerod, A D ^a   Mrowietz, U ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; CYCLOSPORIN; DIMETHYLFUMARATE; ESTER DERIVATIVE; ETRETIN; FUMADERM; FUMARIC ACID; GAMMA GLUTAMYLTRANSFERASE; HYDROGEN; HYDROXYUREA; LIVER ENZYME; MAGNESIUM; METHOTREXATE; METHYL GROUP; MONOETHYL HYDROGEN FUMARATE; PENTOXIFYLLINE; UNCLASSIFIED DRUG; ZINC DERIVATIVE;

CELL COUNT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ENZYME BLOOD LEVEL; EOSINOPHILIA; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; HUMAN; LYMPHOCYTOPENIA; MICROMOLECULAR TUBULAR PROTEINURIA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; REVIEW; SIDE EFFECT; STOMACH PAIN;

DERMATOLOGIC AGENTS; ESTERS; FUMARATES; HUMANS; PSORIASIS; T-LYMPHOCYTES;

EID: 2342509066     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2004.05903.x     Document Type: Review

References (18)

1. Hoefnagel JJ, Thio HB, Willemze R et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
2. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424-9.
3. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis including experience of use in combination with other systemic modalities. Br J Dermatol doi: 10.1111/j.0007-0963.2004.05739.
4. Nugteren-Huying WM, van der Schroeff JG, Hermans J et al. [Fumaric acid therapy in psoriasis: a double-blind, placebo-controlled study]. Ned Tijdschr Geneeskd 1990; 134: 2387-91.
5. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
6. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
7. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138: 456-60.
8. Friedrich M, Sterry W, Klein A et al. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Derm Venereol 2001; 81: 429-30.
9. Boesken WH, Oser B, Roth J et al. Nephrotoxische Wirkungen durch Fumarsäure-Derivate in der Behandlung der Psoriasis vulgaris. Nieren Hochdruckkrankheiten 1998; 27: 145-50.
10. Hohenegger M, Vermes M, Sadjak A et al. Nephrotoxicity of fumaric acid monoethylester (FAME). Adv Exp Med Biol 1989; 252: 265-72.
11. Fliegner L, Spiegel P. Osteomalazie als offenbar seltene Nebenwirkung der oralen Fumarsäuretherapie. Hautarzt 1992; 43: 554-60.
12. Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383-8.
13. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390-5.
14. de Jong R, Bezemer AC, Zomerdijk TP et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-74.
15. Litjens NH, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-51.
16. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116: 203-8.
17. Loewe R, Holnthoner W, Groger M et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781-7.
18. Vandermeeren M, Janssens S, Wouters H et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001; 116: 124-30.